New stock news | Bangshun Pharmaceutical's Hong Kong IPO prospectus has expired
Hangzhou Bangshun Pharmaceutical Co., Ltd. (hereinafter referred to as "Bangshun Pharmaceutical") submitted its Hong Kong IPO prospectus on January 22, 2026, which was valid for 6 months and expired on July 22, 2026. China International Capital Corporation Limited was its exclusive sponsor.
Hangzhou Bangshun Pharmaceutical Co., Ltd. (hereinafter referred to as Bangshun Pharmaceutical) submitted its Hong Kong stock prospectus on January 22, 2026, which expired after 6 months on July 22, 2026. China Securities Co., Ltd. International was its exclusive sponsor.
The prospectus shows that Bangshun Pharmaceutical is a biotechnology company focusing on the fields of oncology and autoimmune diseases. The company has established a pipeline including a new drug application (NDA) stage candidate drug (bezitexetanib), a registration-stage clinical candidate drug (CX1440), and five preclinical stage candidate drugs (CX03, CX12, CX13, CX15, and CX16).
Related Articles
Haier Smart Home (06690) spent 42.288 million yuan on July 24 to repurchase 1.94 million A shares.
SINOPEC CORP (00386) spent 5.184 million yuan on July 24 to repurchase 1 million A shares.
GUSHENGTANG (02273) spent approximately HK$2.2085 million on July 24th to repurchase 77,800 shares.
Haier Smart Home (06690) spent 42.288 million yuan on July 24 to repurchase 1.94 million A shares.
SINOPEC CORP (00386) spent 5.184 million yuan on July 24 to repurchase 1 million A shares.
GUSHENGTANG (02273) spent approximately HK$2.2085 million on July 24th to repurchase 77,800 shares.
RECOMMEND
